Skip to main content

Table 1 Clinical data of SCI patients

From: HAL® exoskeleton training improves walking parameters and normalizes cortical excitability in primary somatosensory cortex in spinal cord injury patients

Case

Sex

Age (in years)

Time since injury (in years)

Etiology

Level

ASIA classification/ZPP

Current medication

1

M

40

13

T7/8#

T8

C

Tolterodine 4 mg/day

2

M

63

1

T12#

L1

B/L3

Trospium chloride (unknown dosage)

3

M

36

1

T11/12#

T12

A/L3

Oxybutynin 20 mg/day

4

F

55

1

L1#

L1

C

Thyroxine 75 μg/day, pregabalin 150 mg/day, methionine 1500 mg/day

5

M

42

16

L1#

L1

A/L3

Oxybutynin 15 mg/day, methionine 1500 mg/day

6

M

52

10

L3#

L2

A/L3

Methionine 1000 mg/day, calcium (unknown dosage), cranberry capsules 2/day, alendronic acid 70 mg/once a week

7

F

40

19

L1#

T11

A/S1

N0ne

8

M

56

0.7

L1#

T12

C

Trospium chloride 30 mg/day, amlodipine 5 mg/day, domperidone 10 mg/day

(8.5 months)

9

F

36

8

L1#

L1

A/L3

None

10

M

52

10

L1#

L1

C

Ramipril 5 mg/day, amlodipine 5 mg/day, oxybutynin 20 mg/day

11

F

44

17

L1#

L1

C

None

  1. M = male, f = female, # = fracture, ASIA = American Spinal Injury Association, ZPP = zone of partial preservation, T = thoracic, L = lumbal, S = sacral